Posted by Michael Wonder on 19 Nov 2024
Alkeus Pharmaceuticals receives FDA rare paediatric disease and fast track designations for gildeuretinol as a treatment for Stargardt disease
18 November 2024 - Alkeus Pharmaceuticals today announced that gildeuretinol (ALK-001), an investigational oral therapy, has received rare paediatric disease and fast track designations from the US FDA for the treatment of Stargardt disease.
Oral gildeuretinol acetate (ALK-001) is a new chemical entity designed to reduce the dimerisation of vitamin A without modulating the visual cycle.
